Lilly’s Retevmo Cuts Recurrence Risk by 83% in NSCLC
INDIANAPOLIS, Indiana, May 31, 2026 Eli Lilly and Company has announced groundbreaking results from the pivotal Phase 3 LIBRETTO-432...
licensing deal
Advertisement
Hanmi and Lilly Strike $1.26 Billion Deal for Promising GLP-2 Drug Candidate Sonefpeglutide
SEOUL, South Korea, June 1, 2026 Hanmi Pharm. Co., Ltd. has entered into a landmark global licensing agreement with...
HanchorBio Expands Global Growth Strategy With Taiwan Listing and HCB101 Clinical Progress
TAIPEI, Taiwan, SHANGHAI, China and SAN FRANCISCO, California — May 28, 2026 HanchorBio, Inc. announced that the company will...
Arrowhead Pharmaceuticals and Madrigal Announce MASH Deal
PASADENA, Calif., United States – May 5, 2026 Arrowhead Pharmaceuticals Inc. has entered into an exclusive global licensing agreement...
Cue Biopharma Expands Anti-IgE Pipeline in $691M Deal
Boston, USA | April 30, 2026 Cue Biopharma has entered into a strategic licensing agreement with Ascendant Health Sciences...
Advertisements
Dogwood Therapeutics Secures $100M Partnership for Antiviral Assets
Alpharetta, Georgia, USA – April 23, 2026 Dogwood Therapeutics announced a global development and commercialization partnership with PRIDCor Therapeutics...
Aligos-Amoytop $445M HBV Licensing Deal Expands Access
SOUTH SAN FRANCISCO, Calif., April 16, 2026 Aligos Therapeutics has entered into an exclusive licensing agreement with Xiamen Amoytop...
Merck Partners Infinimmune in $838M Antibody Discovery Deal
RAHWAY, N.J., USA — March 31, 2026 Merck & Co. has entered into a strategic antibody discovery collaboration with...
Frontier Licenses p53 Cancer Drug FMC-220 to LG Chem
BOSTON & SOUTH SAN FRANCISCO, Calif., USA, April 1, 2026 Frontier Medicines has announced an exclusive global licensing agreement...
Advertisement
